**Title: Kolmar BNH Earns “Zero Deficiency” Rating from FDA for HemoHim Production**
Kolmar BNH (KRX: 200130), a leading South Korean original design manufacturer, has received international recognition for its immune-boosting dietary supplement, HemoHim. The U.S. Food and Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA) have both acknowledged the superior quality of HemoHim, enhancing its credibility in the global market.
Notably, Kolmar BNH’s Seoul manufacturing facility underwent a rigorous FDA audit in September, achieving a coveted “No Action Indicated” (NAI) rating, signifying zero deficiencies. This classification attests to the facility’s adherence to the stringent Good Manufacturing Practices (cGMP) standards mandated by the U.S. Such recognition boosts Kolmar BNH’s competitive edge in the health and nutrition supplement industry, reinforcing its status as a world-class original design manufacturer (ODM).
The FDA’s audit was prompted by the increasing volumes of HemoHim exports to the U.S., and it provided a thorough evaluation of Kolmar BNH’s quality control capabilities. The NAI rating reflects comprehensive scrutiny of key areas, including manufacturing processes, hygiene standards, quality control procedures, and employee training.
HemoHim, a low-acid liquid dietary supplement, underwent extensive testing across various parameters, including raw material quality control, pH balance, and stability, achieving perfect scores